logo

MYRIAD GEN(NSDQ:MYGN)
Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.
# Employees: 869
Address: 320 Wakara Way,Salt Lake City,UT,USA
Phone: 801 584-3600
Fax: 801 584-3640
Website: www.myriad.com
Email: info@myriad.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
John T. Henderson M.D. (Chmn.)
Walter Gilbert Ph.D. (Vice-Chmn.)
Peter D. Meldrum (Presi.; C.E.O.; Dir.)
James S. Evans (C.F.O.)
Mark H. Skolnick Ph.D. (Chief Scientific Off.; Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/9/2010
Mean EPS (Next Qtr): $0.35
Mean EPS (Year): $1.49
Mean Estimate(Long Term): $23.25
P/E Ratio(Based on EPS estimate): 15.890
Number of Estimates: 16
Shares Performance
Period MYGN Compare to S&P
YTD -28.76 % -41.04 %
4 Weeks -9.54 % -10.52 %
12 Weeks -23.03 % -27.43 %
Shares Information
Analyst Coverage: Y
Avg Volume: 2130596
Shares Outstanding: 96M
Market Cap: $2.27B
52 Week High: $46.00
52 Week Low: $22.85
P/E Ratio: 20.610
PEG Ratio: 0.680
Split: On 3/26/2009 MYGN split by factor of 2.000
Earnings Performance
EPS Growth in Last Quarter: -16.22 %
EPS Growth in Last Year: 106.67 %
Sales Growth in Last Quarter: -1.11 %
Sales Growth in Last Quarter: 15.58 %
Financials
Qtr Book Value: $4.79
Cash Flow/Share: $15.52
Change in Payout Ratio: 0.000
Price/Sales: 6.610
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia